CANbridge Pharmaceuticals begins CAN103 phase 1/2 trial in Gaucher disease
CANbridge Pharmaceuticals said that it has dosed the first patient in a phase 1/2 trial of CAN103 in treatment-naïve patients in China having Gaucher disease ... Read More
CANbridge doses first patient in phase 2 EMBARK study of CAN108 in BA
CANbridge Pharmaceuticals has dosed the first patient in the phase 2 EMBARK study of CAN108 (maralixibat) in biliary atresia (BA) in China. The clinical trial ... Read More